Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Phase 3positiveIvonescimabPembrolizumabPositive
AI Analysis
Summary
Akeso announced that ivonescimab met the key secondary overall survival endpoint in the Phase 3 HARMONi-2 trial, showing statistically significant and clinically meaningful benefit compared to pembrolizumab in first-line PD-L1-positive NSCLC.
Clinical Trial Data
Phase
Phase 3
NCT ID
Outcome Details
Met key secondary endpoint of overall survival in interim analysis, demonstrating statistically significant and clinically meaningful benefit versus pembrolizumab
Importance:8/10
Sentiment:
0.85
oncologyNSCLCimmunotherapyinterim analysisoverall survival
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 2, 2026 9:00 PM